The chemical conglomerate is the second firm to license CRISPR/Cas9 from the Broad after Monsanto.
The program will provide two young scientists with funding for independent research as well as resources to help them commercialize their technology.
The gene-gene interactions research could lead to new therapies targeting cells with particular mutations, or combinations of targeted therapies.
The Croatan algorithm uses the random forest machine learning method to evaluate guide RNAs for use in CRISPR knockout experiments.
The company intends to use part of the proceeds of the offering to advance programs including one in Leber congenital amaurosis 10.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.